BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of transformative medicines targeting well-characterized genetic diseases and genetically driven cancers. Founded in 2015 and headquartered in Palo Alto, California, the company employs a distinctive "hub-and-spoke" business model. This structure allows autonomous, focused teams (the spokes) to advance individual therapeutic programs with agility, while leveraging the clinical, regulatory, and commercial infrastructure of the central parent company (the hub) to optimize capital allocation and reduce investment risk.
BridgeBio's revenue is primarily generated from product sales and royalty agreements. Its flagship commercial product is Attruby (acoramidis), an oral small molecule transthyretin (TTR) stabilizer approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), which has become a significant revenue driver for the company. The company also markets Nulibry (fosdenopterin) for molybdenum cofactor deficiency type A. Beyond its commercialized products, BridgeBio maintains a robust clinical pipeline spanning Mendelian disorders, oncology, and gene therapy. Key late-stage investigational candidates include encaleret for autosomal dominant hypocalcemia type 1 (ADH1), BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), and low-dose infigratinib for achondroplasia.
The company operates primarily in the United States but is expanding its global footprint through strategic licensing and collaboration agreements with major pharmaceutical companies such as Bayer, Novartis, and Kyowa Kirin. By focusing on diseases where the underlying genetic biology is clear, BridgeBio aims to improve the probability of clinical success and bring targeted therapies to underserved patient populations.
